Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
- Conditions
- CNS Embryonal TumorCNS, MedulloblastomaAtypical Teratoid Rhabdoid TumorMedulloblastoma, ChildhoodMedulloblastoma, Group 3Medulloblastoma, Group 4PineoblastomaEmbryonal Tumor With Abundant Neuropil and True RosettesEpendymoblastomaMedulloepithelioma
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- C17 Council
- Target Recruit Count
- 15
- Registration Number
- NCT06942039
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Echocardiography TestProcedure: LeukapheresisProcedure: Multigated Acquisition ScanOther: Questionnaire Administration
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 70
- Registration Number
- NCT06930352
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Conditions
- Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaAcute Undifferentiated LeukemiaMixed Phenotype Acute LeukemiaRecurrent Acute Undifferentiated LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- Procedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Chest RadiographyProcedure: Echocardiography TestProcedure: Hematopoietic Cell TransplantationProcedure: Multigated Acquisition ScanProcedure: PheresisRadiation: Total-Body IrradiationProcedure: Biospecimen Collection
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06928662
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeLymphoblastic Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Lumbar PunctureProcedure: Positron Emission Tomography
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 53
- Registration Number
- NCT06918431
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)
- Conditions
- Core Binding Factor Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Echocardiography TestProcedure: Multigated Acquisition Scan
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 162
- Registration Number
- NCT06917911
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- Conditions
- Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 RearrangementsRecurrent High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Nodal Marginal Zone LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Multigated Acquisition Scan
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 25
- Registration Number
- NCT06905509
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Lumbar Puncture
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT06895473
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
- Conditions
- Relapsed/Refractory AML
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 172
- Registration Number
- NCT06763666
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
BRAZAN Trial in Frontline MCL
- Conditions
- Mantle Cell LymphomaLymphoma
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Christine Ryan
- Target Recruit Count
- 60
- Registration Number
- NCT06854003
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
- Conditions
- AMLRUNX1-RUNX1T1 Fusion Protein Expression
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 300
- Registration Number
- NCT06744504
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.